ChromaDex Corporation
General ticker "CDXC" information:
- Sector: Health Care
- Industry: Life Sciences Tools & Services
- Capitalization: $357.0M (TTM average)
ChromaDex Corporation follows the US Stock Market performance with the rate: 46.1%.
Estimated limits based on current volatility of 4.8%: low 5.59$, high 6.15$
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [4.58$, 8.73$]
- 2025-12-31 to 2026-12-31 estimated range: [3.64$, 7.22$]
Financial Metrics affecting the CDXC estimates:
- Negative: Non-GAAP EPS, $ of 0.04 <= 0.04
- Negative: Industry operating cash flow per share per price (median), % of 0.98 <= 2.82
- Negative: Shareholder equity ratio, % of 67.51 > 63.75
- Positive: 8.37 < Operating profit margin, % of 12.55
- Negative: negative Industry operating income (median)
Short-term CDXC quotes
Long-term CDXC plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $72.05MM | $83.57MM | $61.59MM |
| Operating Expenses | $90.68MM | $89.17MM | $53.86MM |
| Operating Income | $-18.63MM | $-5.60MM | $7.73MM |
| Non-Operating Income | $2.09MM | $0.66MM | $1.13MM |
| R&D Expense | $4.83MM | $4.96MM | $6.02MM |
| Income(Loss) | $-16.54MM | $-4.94MM | $8.86MM |
| Taxes | $0.00MM | $0.00MM | $0.30MM |
| Profit(Loss)* | $-14.45MM | $-4.94MM | $8.55MM |
| Stockholders Equity | $28.67MM | $28.46MM | $46.09MM |
| Inventory | $14.68MM | $14.53MM | $9.19MM |
| Assets | $54.06MM | $54.96MM | $68.28MM |
| Operating Cash Flow | $-15.10MM | $7.12MM | $12.11MM |
| Capital expenditure | $0.33MM | $0.15MM | $0.16MM |
| Investing Cash Flow | $-0.33MM | $-0.14MM | $-0.14MM |
| Financing Cash Flow | $7.65MM | $-0.09MM | $5.37MM |
| Earnings Per Share** | $-0.21 | $-0.07 | $0.11 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.